|Articles|June 14, 2008

Cervical Cancer: Burden of Illness
Volume 14
Issue 6 Suppl

Participating Faculty

Robert J. Lipsy, PharmD, BCPS, FASHP

Assistant Professor

Department of Pharmacy Practice and Sciences

College of Pharmacy

University of Arizona

Tucson, Arizona

Cheryl F. MacDonald, MSN, MPH, CRNP

Clinical Consultant

Newtown Square, Pennsylvania

Jennifer S. Smith, PhD, MPH

Research Assistant Professor

Department of Epidemiology

University of North Carolina at Chapel Hill

School of Public Health

Chapel Hill, North Carolina

GlaxoSmithKline

This publication was made possible by an educational grant from

Download PDF: Participating Faculty

Articles in this issue

about 18 years ago

Article

Ethnic Disparities in Cervical Cancer Illness Burden and Subsequent Care: A Prospective View

about 18 years ago

Article

Assessing Secondary Prevention Methods for Cervical Cancer: Costs and Benefits in Managed Care

about 18 years ago

Article

Introduction

about 18 years ago

Article

Assessing the Short-term and Long-term Burden of Illness in Cervical Cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Participating Faculty

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia

Medicaid MFN Pricing Could Save $8.6 Billion

Active US Drug Shortages Rise for Third Straight Quarter

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

Access Barriers, Not Science, Slow Retina Care: Paul Hahn, MD